The Group is progressing as planned with the construction of the new OxBox bioprocessing facility, with production expected to commence in the first half of 2020.
The Group’s planned Phase I and Phase 2 expansion will fit out around 45,000 sqft (4,200 sqm) with four GMP clean room suites and two fill and finish suites as well as offices, warehousing and QC laboratories, with space available for future expansion.
The development and fit out of the new facility is progressing as planned with completion of the building phase by year end 2019. Following validation batches and expected regulatory approval, the site is expected to be fully operational by the end of the second quarter 2020.
The Company believes that this expansion plan will be sufficient to service the rapidly growing global demand for lentiviral vectors and requirements for the foreseeable future.
In December 2018, the Group also signed a lease on a 32,000 sqft building adjacent to Windrush Court. This new discovery and innovation facility named the Windrush Innovation Centre will be staffed by multidisciplinary teams that will focus on driving innovations and technological advances to support both the product pipeline and the LentiVector® platform. Teams started to move into the facility in the second quarter of 2019 with further refurbishment and fit out taking place over the coming 12 months to make the new centre fully operational.
Our bespoke biomanufacturing suites currently total 1,200m2 (12,917ft2) across three independent clean rooms, with potential for further expansion as required. We operate both cell factories and next generation single-use 200 litre bioreactors in dedicated production suites. These provide capacity for our internal programmes, as well as development and production for our partners, including our flagship collaboration with Novartis on its lead CAR-T therapies.
Our bioprocessing capabilities are supported by our process development, analytics and quality laboratories. Our GMP/GLP accredited facilities include:
• Bio-safety category three (BSL-C3) labs
• Tissue culture and cell engineering laboratories
• Process R&D labs
• QC chemistry and microbiology labs
• Analytical services and clinical analysis laboratories
• PCR, HPLC and FACS suites